Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The proportions of folate (80.0% vs. 50.4%; P < 0.001), vitamin B12 (80.0% vs. 51.2%; P < 0.001), and ferritin tests (60.0% vs. 39.2%; P = 0.004) were significantly higher in the micronutrient deficiency group while 25-OH-vitamin D test was lower than the non-deficiency group (83.8% vs. 94.4%; P = 0.013).

Source: Patient characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A total of 3,490 patients were excluded from our study for the following reasons: (1) patients did not undergo micronutrient testing during the study period (n = 3,047); (2) patients underwent micronutrient blood testing only once (n = 426); (3) data were not available or were lost to follow-up (n = 10); and (4) patients diagnosed with other diseases such as cancer or non-specific inflammation after evaluation (n = 7) (Fig.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Incidence and risk factors of micronutrient deficiency in patients with IBD and intestinal Behçet’s disease: folate, vitamin B12, 25-OH-vitamin D, and ferritin

Study design awaiting verification · BMC Gastroenterology · 2021

Original publication title

Incidence and risk factors of micronutrient deficiency in patients with IBD and intestinal Behçet’s disease: folate, vitamin B12, 25-OH-vitamin D, and ferritin

Yong Eun Park; Soo Jung Park; Jae Jun Park; Jae Hee Cheon; TaeIl Kim; Won Ho Kim

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In conclusion, in patients with IBD and intestinal BD, the incidence of micronutrient deficiency was high (39.0%). In addition, CD, a history of intestinal surgery, and young age were factors significantly associated with deficiency. Therefore, those with IBD, especially young patients with CD who have undergone bowel resection, should be observed more carefully to assess the need for supplementation to treat micronutrient deficiencies.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic disease of the gastrointestinal (GI) tract associated with unclear etiology, leading to rectal bleeding, abdominal pain, and weight loss and repeated cycles of relapse and remission [1, 2]. CD is an IBD that can affect entire GI tract from mouth to anus and it affects mainly terminal ileum and colon. It often includes both intestinal and extra-intestinal symptoms [2, 3].

On the other hand, UC is mostly restricted to the colon and it usually involves continuous lesion in the intestinal mucosa [2]. Most patients with IBD, especially those with CD, suffer from weight loss and malnutrition during the course of the disease [4, 5], which may be related to lack of oral intake, increased nutrient requirements, increased GI loss, and intestinal resection or bypass surgery [4, 6]. In addition, intestinal Behçet’s disease (BD), which is an intestinal invasion of BD with chronic relapsing multisystem vasculitis disorder [7], is similar to CD with respect to clinical courses, symptoms and treatment modalities [8].

Therefore, there is increasing interest in patient management and nutritional status in intestinal BD as well as IBD.

Nutrients can be classified as either macronutrients or micronutrients. Macronutrients are energy-providing nutrients including carbohydrates, lipids, and proteins. Malnutrition can occur in cases of active, severe IBD, when macronutrients are not consumed or absorbed in sufficient quantities. Micronutrients, including minerals, vitamins, and trace elements, are often deficient in patients with mild disease activity or remission status [9, 10].

According to the European Society for Clinical Nutrition and Metabolism guidelines, patients with IBD should be regularly checked for micronutrient deficiencies and certain deficits should be adequately corrected [11]. Several studies have reported vitamin and mineral deficiencies in patients with IBD; these studies assessed their symptoms and effects on the quality of life and observed widely variable clinical significance [12Not reported14]. Vitamins are organic compounds and are classified as either water-soluble, including thiamine (B1), riboflavin (B2), nicotinic acid/niacin (B3), pyridoxine (B6), cobalamin (B12), biotin, pantothenic acid, folic acid, and vitamin C (ascorbic acid), or fat-soluble, including vitamins A, D, E, and K [9].

Dietary minerals are important inorganic components that work as cofactors and catalysts in maintaining cell structure and enzymatic processes, such as calcium, phosphate, potassium, magnesium, and iron. Trace elements are necessary for the function of enzymes in the body, including zinc, copper, and selenium [9, 10].

Clinically relevant micronutrient deficiencies that occur over the course of IBD disease progression include anemia (caused by iron, folate, and vitamin B12 deficiencies), bone mineral density loss (due to insufficient calcium, vitamin D, magnesium, and vitamin K levels), impaired thrombosis (caused by folate, vitamin B6, B12 deficiency) and wound healing deficits (due to deficiencies of vitamin A, C, and zinc), and carcinogenesis (related to folate, vitamin D, and calcium deficiency) [9]. Among them, anemia is the most common complication affecting up to 70% of patients with IBD, including UC and CD, and intestinal BD [15, 16].

Iron deficiency is the most common cause of anemia in 30 to 90% of patients with IBD, but folate and vitamin B12 deficiencies are also highly prevalent in these patients, especially in those with CD, compared to the general population [17Not reported19]. In addition, bone density is an important factor, which affects not only the quality of life of IBD patients but also the disease course of IBD, as it is highly related to treatment modalities such as corticosteroids as well as micronutrients [20Not reported22].

However, studies assessing micronutrient concentrations in patients with IBD are scarce, and there are currently no studies on micronutrients in patients with intestinal BD, to our knowledge. Therefore, we aimed to investigate the prevalence and risk factors of micronutrient deficiency in patients with IBD and intestinal BD.

Source: Background Source: Background Source: Background Source: Background

Study methods

What methods does the paper describe?

Patients

We conducted a retrospective study of patients with IBD and intestinal BD who underwent laboratory tests to quantify micronutrients such as iron, folate, vitamin B12, and 25-OH-vitamin D from March 2016 to March 2017 at the Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Out of 3,695 patients, a total of 205 with IBD and intestinal BD who underwent micronutrient testing twice were enrolled retrospectively. A total of 3,490 patients were excluded from our study for the following reasons: (1) patients did not undergo micronutrient testing during the study period (n = 3,047); (2) patients underwent micronutrient blood testing only once (n = 426); (3) data were not available or were lost to follow-up (n = 10); and (4) patients diagnosed with other diseases such as cancer or non-specific inflammation after evaluation (n = 7) (Fig. 1).

Fig. 1

Patients enrollment

Figure image at the original source: open the original paper. This file is not included in this text import.

We included patients who underwent micronutrient testing at least twice, at baseline and at follow-up after 6 months for one or more of the following four micronutrients: folate (n = 127), vitamin B12 (n = 128), 25-OH-vitamin D (n = 184), and ferritin (n = 97). In addition, we divided patients into two groups: a group consisting of those with a micronutrient deficiency (n = 80) and another group with those without micronutrient deficiency (n = 125) at baseline. This study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional review board of Severance Hospital.

Baseline characteristics

Variables of baseline characteristics included demographic information, routes of laboratory tests (outpatients or inpatients), medications, supplements, past bowel surgery, and underlying diseases.

Definitions

We defined deficient levels of folate and vitamin B12 as <3.38 ng/mL (folate N: 3.38 to 48.0 ng/mL) and < 211 pg/mL (vitamin B12 N: 211 to 911 pg/mL), respectively. Iron deficiency was defined as ferritin levels < 10 ng/mL (N: 10 to 291 ng/mL). Serum 25-OH-vitamin D testing was performed to identify vitamin D deficiency, with vitamin D deficiency defined as < 10 ng/mL (50 nmol/L).

In our study, we defined bowel surgery as cases of surgery due to diseases of IBD and intestinal BD only, and excluded all the other causes including diverticulum and foreign body.

Statistical analysis

Variables are expressed as either median (interquartile range, IQR) or n (%). Baseline characteristics were compared using independent Student’s t-tests (or Mann: Whitney tests) for continuous variables, and χ2 tests (or Fisher’s exact tests) were used for categorical variables, as appropriate. Independent predictors of micronutrient deficiency were analyzed using logistic regression analysis. Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were calculated. Data analysis was performed using Statistical Package for the Social Sciences (SPSS) software (version 20.0; SPSS Inc., Armonk, NY, USA).

A P-value < 0.05 was considered statistically significant.

Source: Methods Source: Methods Source: Methods Source: Methods

Results: Patient characteristics

Micronutrient deficiency was observed in 80 (39.0%) of 205 patients who were tested over the year beginning March 2016. Baseline characteristics of the micronutrient deficient and non-deficient groups were analyzed and are summarized in Table 1. Among the micronutrients assessed, 25-OH-vitamin D was quantified in 90.2% of patients, and vitamin B12, folate and ferritin testings were performed for 47.3 to 62.4% of patients. The proportions of folate (80.0% vs. 50.4%; P < 0.001), vitamin B12 (80.0% vs. 51.2%; P < 0.001), and ferritin tests (60.0% vs. 39.2%; P = 0.004) were significantly higher in the micronutrient deficiency group while 25-OH-vitamin D test was lower than the non-deficiency group (83.8% vs. 94.4%; P = 0.013).

The number of subjects found with deficiency of each micronutrient was 10 (12.5%) for folate, 20 (25.0%) for vitamin B12, 21 (26.3%) for 25-OH-vitamin D, and 45 (56.3%) for ferritin in the micronutrient deficiency group. Patients with CD exhibited a greater prevalence of micronutrient deficiency than those with UC or intestinal BD (82.5% vs. 11.3% vs. 6.3%; P = 0.003).

Table 1

Baseline characteristics between micro-nutrient deficiency group and non-deficiency group

VariablesTotal (n = 205)Micro-nutrient deficiency group (n = 80, 39.0%)Non-deficiency group (n = 125, 61.0%)P-value
Male sex118 (57.6)44 (55.0)74 (59.2)0.553
Age34 (19 to 47)27 (19 to 41)37 (20 to 51)0.003
The path of laboratory test0.150
 Outpatients clinic191 (93.2)72 (90.0)119 (95.2)
 Hospitalization patients14 (6.8)8 (10.0)6 (4.8)
Number of micronutrient tests
 Folate127 (62.0)64 (80.0)63 (50.4) < 0.001
 Vitamin B12128 (62.4)64 (80.0)64 (51.2) < 0.001
 25-OH-vitamin D184 (90.2)67 (83.8)117 (94.4)0.013
 Ferritin97 (47.3)48 (60.0)49 (39.2)0.004
Type of IBD0.003
 UC49 (23.9)9 (11.3)40 (32.0)
 CD143 (69.8)66 (82.5)77 (61.6)
 Intestinal BD13 (6.3)5 (6.3)8 (6.4)
Medications
 5-ASA114 (55.6)33 (41.3)81 (64.8)0.001
 Steroids12 (5.9)3 (3.8)9 (7.2)0.305
 Azathioprine66 (32.2)32 (40.0)34 (27.2)0.056
 Anti-TNF101 (49.3)45 (56.3)56 (44.8)0.110
 Methotrexate33 (16.1)11 (13.8)22 (17.6)0.464
 6-MP2 (1.0)0 (0)2 (1.6)0.256
 Othersa12 (5.9)2 (2.5)10 (8.0)0.102
Supplementary medications
 Iron supplementation77 (37.6)43 (53.8)34 (27.2) < 0.001
 Folate supplementation50 (24.4)26 (32.5)24 (19.2)0.031
 Multivitamin52 (25.4)21 (26.3)31 (24.8)0.816
 Calcium, Vitamin D supplementation127 (62.0)51 (63.7)76 (60.8)0.671
 Vitamin B12 supplementation43 (21.0)30 (37.5)13 (10.4) < 0.001
 Vitamin C supplementation3 (1.5)0 (0)3 (2.4)0.163
 Zinc supplementation7 (3.4)3 (3.8)4 (3.2)0.832
 Osteoporosis medication
 SERM3 (1.5)1 (1.3)2 (1.6)0.839
 Bisphosphonate14 (6.8)1 (1.3)13 (10.4)0.011
Operation65 (31.7)33 (41.3)32 (25.6)0.019
Underlying disease
 Hypertension4 (2.0)1 (1.3)3 (2.4)0.561
 Diabetes1 (0.5)0 (0)1 (0.8)0.423
 Osteoporosis38 (18.5)13 (16.3)25 (20.0)0.500
 Othersb46 (22.4)19 (23.8)27 (21.6)0.719

Data are expressed as median (interquartile range, IQR) or n (%). *P-value for comparing patients with micronutrient deficiency group and non-deficiency group

IBD, Inflammatory bowel disease; UC, Ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor; 6-MP, 6-mercaptopurine; SERM, Selective estrogen receptor modulators

aMongersen, vedolizumab

bMyelodysplastic syndrome, Systemic lupus erythematosus, aortic valve disease, Bronchiolitis obliterans with organizing pneumonia, osteoarthritis, coronary artery occlusive disease, cancer

The median age was 34 years [IQR, 19 to 47], and 57.6% of the enrolled patients were male. In addition, most patients underwent laboratory testing in an outpatient clinic setting compared to an inpatient setting (93.2% vs. 6.8%; P = 0.150). There were no significant differences in most of the types of medications used by patients, but there were significantly more users of 5-aminosalicylic acid (5-ASA) in the non-deficient group (41.3% vs. 64.8%; P = 0.001). Micronutrient deficiency was higher in patients who underwent previous bowel surgery to treat the disease than in those who had not previously undergone disease-related surgery (41.3% vs. 25.6%; P = 0.019) (Table 1).

Source: Patient characteristics Source: Patient characteristics

Results: Relative risk of micronutrient deficiency

Based on the univariate analysis, variables that were negatively associated with micronutrient deficiency with statistical significance included age (OR, 0.975; 95% CI 0.958 to 0.993; P = 0.006) and 5-ASA usage (OR, 0.381; 95% CI 0.214 to 0.679; P = 0.001). In addition, CD (compared to those with UC or intestinal BD) (OR, 3.810; 95% CI 1.721 to 8.430; P = 0.001) and previous disease-related surgical operations (OR, 2.041; 95% CI 1.120 to 3.717; P = 0.020) were significantly associated with micronutrient deficiency (Table 2). Based on the multivariate analysis assessing variables including male sex, age, the path of laboratory test, types of intestinal disease, medications, previous surgical operations, and other underlying diseases, CD (compared with UC or intestinal BD) (adjusted OR, 2.492; 95% CI 1.012 to 6.136; P = 0.047) and previous disease-related surgical operations (adjusted OR, 2.714; 95% CI 1.260 to 5.844; P = 0.011) were identified to be associated with higher risks of micronutrient deficiency.

Conversely, age (adjusted OR, 0.973; 95% CI 0.949 to 0.998; P = 0.037) was negatively associated with micronutrient deficiency (Table 2).

Table 2

Relative risk of micro-nutrient deficiency

VariableUni-variate analysisMulti-variate analysis
OR (95% CI)P-valueAdjusted OR (95% CI)P-value
Male sex0.842 (0.478 to 1.485)0.5530.718 (0.375 to 1.376)0.319
Age0.975 (0.958 to 0.993)0.0060.973 (0.949 to 0.998)0.037
The path of laboratory test
 Outpatients clinic1.0 (Ref.)1.0 (Ref.)
 Hospitalization patients2.204 (0.735 to 6.608)0.1582.459 (0.715 to 8.461)0.154
Type of disease
 UC1.0 (Ref.)1.0 (Ref.)
 CD3.810 (1.721 to 8.430)0.0012.492 (1.012 to 6.136)0.047
 Intestinal BD2.778 (0.734 to 10.513)0.1321.356 (0.284 to 6.479)0.703
Medications
 5-ASA0.381 (0.214 to 0.679)0.0010.548 (0.281 to 1.068)0.077
 Steroids0.502 (0.132 to 1.914)0.313
 Azathioprine1.784 (0.983 to 3.238)0.057
 Anti-TNF1.584 (0.900 to 2.788)0.111
 Methotrexate0.746 (0.340 to 1.637)0.465
 Othersa0.295 (0.063 to 1.383)0.121
Operation2.041 (1.120 to 3.717)0.0202.714 (1.260 to 5.844)0.011
Underlying disease
 Hypertension0.515 (0.053 to 5.037)0.568
 Osteoporosis0.776 (0.371 to 1.624)0.5011.500 (0.699 to 3.217)0.298
 Othersb1.131 (0.579 to 2.206)0.7192.459 (0.715 to 8.461)0.154

OR, odds ratio; CI, confidence interval; UC, Ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor

aMongersen, vedolizumab

bMDS, SLE, AR, BOOP, OA, Osteoporosis, CAOD, cancer

Source: Relative risk of micronutrient deficiency

Results: Changes in micronutrient levels

Patients with UC and CD had the highest rates of ferritin deficiency compared to the other micronutrients assessed, including vitamin B12, folate, and 25-OH-vitamin D, while in those with intestinal BD, the deficiency did not vary among the micronutrients assessed. However, rates of vitamin B12 deficiency significantly differed among those with UC, CD, and intestinal BD (0% vs. 13.7% vs. 18.2%, respectively; P = 0.038) (Fig. 2).

Fig. 2

Frequency of micronutrient deficiency (folate, vitamin B12, 25-OH-vitamin D, and ferritin) for each disease, including ulcerative colitis (UC), Crohn’s disease (CD), and intestinal Behçet’s disease (BD)

Figure image at the original source: open the original paper. This file is not included in this text import.

We assessed changes from baseline at the first 6-month follow-up in terms of folate, vitamin B12, 25-OH-vitamin D, and ferritin levels in this study population. Initial laboratory tests in patients with UC showed ferritin and 25-OH-vitamin D deficiency, which had improved at follow-up testing after supplementation. In patients with CD, ferritin, vitamin B12, 25-OH-vitamin D, and folic acid deficiency occurred, and ferritin deficiency was the highest. Patients with intestinal BD had more deficiencies in folic acid and vitamin B12 than ferritin and 25-OH-vitamin D.

In all cases, deficiencies were treated at the time of discovery, and after 6 months, all micronutrient deficiencies were reduced (Fig. 3).

Fig. 3

Changes in micronutrient deficiencies (folate, vitamin B12, 25-OH-vitamin D, and ferritin) between the initial and follow-up blood tests after six months in patients with ulcerative colitis (UC), Crohn’s disease (CD), and intestinal Behçet’s disease (BD)

Figure image at the original source: open the original paper. This file is not included in this text import.

Source: Changes in micronutrient levels Source: Changes in micronutrient levels

Discussion

The study found that micronutrient deficiency was high (39.0%) in patients with IBD and intestinal BD, and 83% of the deficiency group were CD patients. In IBD patients with CD or UC, ferritin deficiency was significant, as was 25-OH-vitamin D deficiency. However, patients with intestinal BD had more folic acid and vitamin B12 deficiencies than those with IBD, who had more ferritin and 25-OH-vitamin D deficiencies. In addition, young age, CD, and intestinal surgery were significantly associated with micronutrient deficiency.

Hwang et al. reviewed studies on micronutrient deficiency in patients with IBD and showed prevalence of micronutrients deficiencies. Among IBD patients, water-soluble vitamins deficiencies have been reported up to 11 to 78% [19, 23Not reported25]; fat-soluble vitamins deficiencies to 22 to 90% [22, 23, 25Not reported28]; and macro mineral deficiencies to 36 to 90% [15, 23, 24, 29Not reported31]. In most studies, patients with CD showed a higher correlation with vitamin or mineral deficiencies than those with UC.

Our study also showed a high prevalence (46.2%, 66 of 143 patients) of micronutrient deficiency in patients with CD. Most vitamins and minerals are absorbed in the proximal small intestine, and vitamin B12 is absorbed in the terminal ileum [9]. The distal ileum is also where bile acid absorption occurs, which is important for the absorption of fat and fat-soluble vitamins [9]. Therefore, micronutrient deficiency should be carefully observed in patients with CD, which is relatively invasive in the small intestine and frequently affects the terminal ileum.

In addition, caution should also be exercised in cases of intestinal BD because it often manifests as an oval shape and causes deep ulcers in the ileocecal area [7]. Therefore, patients with intestinal BD also showed micronutrient deficiencies (38.46%, 5 of 13), especially vitamin B12 deficiency; there was a significant difference among patients with UC, CD, and intestinal BD, with the highest prevalence in patients with intestinal BD (UC, 0% vs. CD, 13.7% vs. intestinal BD, 18.2%; P = 0.038) (Fig. 2b).

The mostly likely explanation could be due to the location of the intestine affected by the disease, as intestinal BD may be associated with high cobalamin (vitamin B12) deficiency rates. Therefore, 156 patients with CD and intestinal BD with similar invasion sites were analyzed separately, but there was no significant difference in the deficiency of micronutrients between CD and BD patients. However, our results showed that micronutrient deficiency was as high in patients with intestinal BD as well as in patients with CD.

Further research is needed in a larger study group.

In patients with IBD, surgery is a significantly important factor affecting the likelihood of micronutrient deficiency. There have been reports of significantly lower vitamin D levels when CD affects the small intestine or when the small intestine is excised [32]. Active Crohn's ileitis and small bowel resection are reported to be risk factors for folic acid deficiency, as they can lead to malabsorption [19, 25]. In addition, Battat et al. reported that ileal resection greater than 30 cm was an associated risk factor for cobalamin deficiency in patients with CD [33].

When further analyzing the risk factors for cobalamin deficiency in our study population, disease-related surgical operation was found to be a significant associated risk factor (OR, 5.513; CI 1.829 to 16.613; P = 0.002; data not shown).

Our study is the first report on micronutrient deficiency in patients with intestinal BD and IBD. However, the study has several limitations. First, it is a retrospective cross-sectional study with selection bias. Because we examined patients who had been tested for a period of 1 year, we could not observe the cumulative effects of time to compare what the deficiencies had been before the start of the study and whether the deficiency occurred again after it ended, even though the deficiencies had been treated.

This also showed a limit to the outcome of the assessment of patients with vitamin D deficiency. Even though our study used a lower vitamin D deficiency criterion (< 10 ng/mL) than other studies, many patients were already taking supplements (62.0%), which made it difficult to make a clear comparison. In addition, it may include cases in which several micronutrients are deficient in one patient with high risk of micronutrient deficiency. Furthermore, deficiency of certain micronutrients such as vitamin B12 can be affected depending on the location of the disease.

For example, CD and intestinal BD patients are at high risk of vitamin B12 deficiency, while UC patients are relatively less likely to be affected. Therefore, there is a limitation with the possibility of selection bias. However, it is meaningful that it can analyze the risk of overall micronutrients deficiency. Second, we could not examine the relationship between disease activities. In particular, data on ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) levels, medical records of disease activity (CDAI [Crohn's disease activity index], Mayo score, DAIBD [Disease Activity Index for Intestinal Behcet's Disease]), and disease extent (Montreal classification) were insufficient for analysis.

Most were outpatient clinic patients (93.2%), so we could not obtain accurate disease information based solely on the medical records. For example, 55.6% of the included patients were being treated with Pentasa (5-ASA) and 5.9% of patients were treated with steroid medications, suggesting most patients were not in the acute phase of disease progression. Thus, it may have been difficult to clearly compare differences in micronutrient deficiencies among those treated with various medications. Nevertheless, it was found that micronutrient deficiency was high in the outpatient population where the disease activity was not severe.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion

Results

Patient characteristics

Micronutrient deficiency was observed in 80 (39.0%) of 205 patients who were tested over the year beginning March 2016. Baseline characteristics of the micronutrient deficient and non-deficient groups were analyzed and are summarized in Table 1. Among the micronutrients assessed, 25-OH-vitamin D was quantified in 90.2% of patients, and vitamin B12, folate and ferritin testings were performed for 47.3 to 62.4% of patients. The proportions of folate (80.0% vs. 50.4%; P < 0.001), vitamin B12 (80.0% vs. 51.2%; P < 0.001), and ferritin tests (60.0% vs. 39.2%; P = 0.004) were significantly higher in the micronutrient deficiency group while 25-OH-vitamin D test was lower than the non-deficiency group (83.8% vs. 94.4%; P = 0.013).

The number of subjects found with deficiency of each micronutrient was 10 (12.5%) for folate, 20 (25.0%) for vitamin B12, 21 (26.3%) for 25-OH-vitamin D, and 45 (56.3%) for ferritin in the micronutrient deficiency group. Patients with CD exhibited a greater prevalence of micronutrient deficiency than those with UC or intestinal BD (82.5% vs. 11.3% vs. 6.3%; P = 0.003).

Table 1

Baseline characteristics between micro-nutrient deficiency group and non-deficiency group

VariablesTotal (n = 205)Micro-nutrient deficiency group (n = 80, 39.0%)Non-deficiency group (n = 125, 61.0%)P-value
Male sex118 (57.6)44 (55.0)74 (59.2)0.553
Age34 (19 to 47)27 (19 to 41)37 (20 to 51)0.003
The path of laboratory test0.150
 Outpatients clinic191 (93.2)72 (90.0)119 (95.2)
 Hospitalization patients14 (6.8)8 (10.0)6 (4.8)
Number of micronutrient tests
 Folate127 (62.0)64 (80.0)63 (50.4) < 0.001
 Vitamin B12128 (62.4)64 (80.0)64 (51.2) < 0.001
 25-OH-vitamin D184 (90.2)67 (83.8)117 (94.4)0.013
 Ferritin97 (47.3)48 (60.0)49 (39.2)0.004
Type of IBD0.003
 UC49 (23.9)9 (11.3)40 (32.0)
 CD143 (69.8)66 (82.5)77 (61.6)
 Intestinal BD13 (6.3)5 (6.3)8 (6.4)
Medications
 5-ASA114 (55.6)33 (41.3)81 (64.8)0.001
 Steroids12 (5.9)3 (3.8)9 (7.2)0.305
 Azathioprine66 (32.2)32 (40.0)34 (27.2)0.056
 Anti-TNF101 (49.3)45 (56.3)56 (44.8)0.110
 Methotrexate33 (16.1)11 (13.8)22 (17.6)0.464
 6-MP2 (1.0)0 (0)2 (1.6)0.256
 Othersa12 (5.9)2 (2.5)10 (8.0)0.102
Supplementary medications
 Iron supplementation77 (37.6)43 (53.8)34 (27.2) < 0.001
 Folate supplementation50 (24.4)26 (32.5)24 (19.2)0.031
 Multivitamin52 (25.4)21 (26.3)31 (24.8)0.816
 Calcium, Vitamin D supplementation127 (62.0)51 (63.7)76 (60.8)0.671
 Vitamin B12 supplementation43 (21.0)30 (37.5)13 (10.4) < 0.001
 Vitamin C supplementation3 (1.5)0 (0)3 (2.4)0.163
 Zinc supplementation7 (3.4)3 (3.8)4 (3.2)0.832
 Osteoporosis medication
 SERM3 (1.5)1 (1.3)2 (1.6)0.839
 Bisphosphonate14 (6.8)1 (1.3)13 (10.4)0.011
Operation65 (31.7)33 (41.3)32 (25.6)0.019
Underlying disease
 Hypertension4 (2.0)1 (1.3)3 (2.4)0.561
 Diabetes1 (0.5)0 (0)1 (0.8)0.423
 Osteoporosis38 (18.5)13 (16.3)25 (20.0)0.500
 Othersb46 (22.4)19 (23.8)27 (21.6)0.719

Data are expressed as median (interquartile range, IQR) or n (%). *P-value for comparing patients with micronutrient deficiency group and non-deficiency group

IBD, Inflammatory bowel disease; UC, Ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor; 6-MP, 6-mercaptopurine; SERM, Selective estrogen receptor modulators

aMongersen, vedolizumab

bMyelodysplastic syndrome, Systemic lupus erythematosus, aortic valve disease, Bronchiolitis obliterans with organizing pneumonia, osteoarthritis, coronary artery occlusive disease, cancer

The median age was 34 years [IQR, 19 to 47], and 57.6% of the enrolled patients were male. In addition, most patients underwent laboratory testing in an outpatient clinic setting compared to an inpatient setting (93.2% vs. 6.8%; P = 0.150). There were no significant differences in most of the types of medications used by patients, but there were significantly more users of 5-aminosalicylic acid (5-ASA) in the non-deficient group (41.3% vs. 64.8%; P = 0.001). Micronutrient deficiency was higher in patients who underwent previous bowel surgery to treat the disease than in those who had not previously undergone disease-related surgery (41.3% vs. 25.6%; P = 0.019) (Table 1).

Relative risk of micronutrient deficiency

Based on the univariate analysis, variables that were negatively associated with micronutrient deficiency with statistical significance included age (OR, 0.975; 95% CI 0.958 to 0.993; P = 0.006) and 5-ASA usage (OR, 0.381; 95% CI 0.214 to 0.679; P = 0.001). In addition, CD (compared to those with UC or intestinal BD) (OR, 3.810; 95% CI 1.721 to 8.430; P = 0.001) and previous disease-related surgical operations (OR, 2.041; 95% CI 1.120 to 3.717; P = 0.020) were significantly associated with micronutrient deficiency (Table 2). Based on the multivariate analysis assessing variables including male sex, age, the path of laboratory test, types of intestinal disease, medications, previous surgical operations, and other underlying diseases, CD (compared with UC or intestinal BD) (adjusted OR, 2.492; 95% CI 1.012 to 6.136; P = 0.047) and previous disease-related surgical operations (adjusted OR, 2.714; 95% CI 1.260 to 5.844; P = 0.011) were identified to be associated with higher risks of micronutrient deficiency.

Conversely, age (adjusted OR, 0.973; 95% CI 0.949 to 0.998; P = 0.037) was negatively associated with micronutrient deficiency (Table 2).

Table 2

Relative risk of micro-nutrient deficiency

VariableUni-variate analysisMulti-variate analysis
OR (95% CI)P-valueAdjusted OR (95% CI)P-value
Male sex0.842 (0.478 to 1.485)0.5530.718 (0.375 to 1.376)0.319
Age0.975 (0.958 to 0.993)0.0060.973 (0.949 to 0.998)0.037
The path of laboratory test
 Outpatients clinic1.0 (Ref.)1.0 (Ref.)
 Hospitalization patients2.204 (0.735 to 6.608)0.1582.459 (0.715 to 8.461)0.154
Type of disease
 UC1.0 (Ref.)1.0 (Ref.)
 CD3.810 (1.721 to 8.430)0.0012.492 (1.012 to 6.136)0.047
 Intestinal BD2.778 (0.734 to 10.513)0.1321.356 (0.284 to 6.479)0.703
Medications
 5-ASA0.381 (0.214 to 0.679)0.0010.548 (0.281 to 1.068)0.077
 Steroids0.502 (0.132 to 1.914)0.313
 Azathioprine1.784 (0.983 to 3.238)0.057
 Anti-TNF1.584 (0.900 to 2.788)0.111
 Methotrexate0.746 (0.340 to 1.637)0.465
 Othersa0.295 (0.063 to 1.383)0.121
Operation2.041 (1.120 to 3.717)0.0202.714 (1.260 to 5.844)0.011
Underlying disease
 Hypertension0.515 (0.053 to 5.037)0.568
 Osteoporosis0.776 (0.371 to 1.624)0.5011.500 (0.699 to 3.217)0.298
 Othersb1.131 (0.579 to 2.206)0.7192.459 (0.715 to 8.461)0.154

OR, odds ratio; CI, confidence interval; UC, Ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor

aMongersen, vedolizumab

bMDS, SLE, AR, BOOP, OA, Osteoporosis, CAOD, cancer

Changes in micronutrient levels

Patients with UC and CD had the highest rates of ferritin deficiency compared to the other micronutrients assessed, including vitamin B12, folate, and 25-OH-vitamin D, while in those with intestinal BD, the deficiency did not vary among the micronutrients assessed. However, rates of vitamin B12 deficiency significantly differed among those with UC, CD, and intestinal BD (0% vs. 13.7% vs. 18.2%, respectively; P = 0.038) (Fig. 2).

Fig. 2

Frequency of micronutrient deficiency (folate, vitamin B12, 25-OH-vitamin D, and ferritin) for each disease, including ulcerative colitis (UC), Crohn’s disease (CD), and intestinal Behçet’s disease (BD)

Figure image at the original source: open the original paper. This file is not included in this text import.

We assessed changes from baseline at the first 6-month follow-up in terms of folate, vitamin B12, 25-OH-vitamin D, and ferritin levels in this study population. Initial laboratory tests in patients with UC showed ferritin and 25-OH-vitamin D deficiency, which had improved at follow-up testing after supplementation. In patients with CD, ferritin, vitamin B12, 25-OH-vitamin D, and folic acid deficiency occurred, and ferritin deficiency was the highest. Patients with intestinal BD had more deficiencies in folic acid and vitamin B12 than ferritin and 25-OH-vitamin D.

In all cases, deficiencies were treated at the time of discovery, and after 6 months, all micronutrient deficiencies were reduced (Fig. 3).

Fig. 3

Changes in micronutrient deficiencies (folate, vitamin B12, 25-OH-vitamin D, and ferritin) between the initial and follow-up blood tests after six months in patients with ulcerative colitis (UC), Crohn’s disease (CD), and intestinal Behçet’s disease (BD)

Figure image at the original source: open the original paper. This file is not included in this text import.

Source: Results Source: Results Source: Results

Conclusions

In conclusion, in patients with IBD and intestinal BD, the incidence of micronutrient deficiency was high (39.0%). In addition, CD, a history of intestinal surgery, and young age were factors significantly associated with deficiency. Therefore, those with IBD, especially young patients with CD who have undergone bowel resection, should be observed more carefully to assess the need for supplementation to treat micronutrient deficiencies.

Source: Conclusions
Authors’ abstract

Background

Patients with inflammatory bowel disease (IBD) and intestinal Behçet’s disease (BD) are vulnerable to micronutrient deficiencies due to diarrhea-related gastrointestinal loss and poor dietary intake caused by disease-related anorexia. However, few studies have investigated the incidence and risk factors for micronutrient deficiency.

Methods

We retrospectively analyzed 205 patients with IBD who underwent micronutrient examination, including folate, vitamin B12, 25-OH-vitamin D, and/or ferritin level quantification, with follow-up blood tests conducted 6 months later.

Results

Eighty patients (39.0%), who were deficient in any of the four micronutrients, were classified as the deficiency group, and the remaining 125 (61.0%) were classified as the non-deficient group. Compared to those in the non-deficiency group, patients in the deficiency group were much younger, had more Crohn's disease (CD) patients, more patients with a history of bowel operation, and significantly less 5-amino salicylic acid usage. Multivariate analysis revealed that CD and bowel operation were significant independent factors associated with micronutrient deficiency.

Conclusions

The incidence of micronutrient deficiency was high (39.0%). Factors including CD, bowel operation, and younger ages were found to be associated with higher risks of deficiency. Therefore, patients with IBD, especially young patients with CD who have undergone bowel resection surgery, need more attention paid to micronutrition.

Read the full paper

Background

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic disease of the gastrointestinal (GI) tract associated with unclear etiology, leading to rectal bleeding, abdominal pain, and weight loss and repeated cycles of relapse and remission [1, 2]. CD is an IBD that can affect entire GI tract from mouth to anus and it affects mainly terminal ileum and colon. It often includes both intestinal and extra-intestinal symptoms [2, 3].

On the other hand, UC is mostly restricted to the colon and it usually involves continuous lesion in the intestinal mucosa [2]. Most patients with IBD, especially those with CD, suffer from weight loss and malnutrition during the course of the disease [4, 5], which may be related to lack of oral intake, increased nutrient requirements, increased GI loss, and intestinal resection or bypass surgery [4, 6]. In addition, intestinal Behçet’s disease (BD), which is an intestinal invasion of BD with chronic relapsing multisystem vasculitis disorder [7], is similar to CD with respect to clinical courses, symptoms and treatment modalities [8].

Therefore, there is increasing interest in patient management and nutritional status in intestinal BD as well as IBD.

Nutrients can be classified as either macronutrients or micronutrients. Macronutrients are energy-providing nutrients including carbohydrates, lipids, and proteins. Malnutrition can occur in cases of active, severe IBD, when macronutrients are not consumed or absorbed in sufficient quantities. Micronutrients, including minerals, vitamins, and trace elements, are often deficient in patients with mild disease activity or remission status [9, 10].

According to the European Society for Clinical Nutrition and Metabolism guidelines, patients with IBD should be regularly checked for micronutrient deficiencies and certain deficits should be adequately corrected [11]. Several studies have reported vitamin and mineral deficiencies in patients with IBD; these studies assessed their symptoms and effects on the quality of life and observed widely variable clinical significance [12Not reported14]. Vitamins are organic compounds and are classified as either water-soluble, including thiamine (B1), riboflavin (B2), nicotinic acid/niacin (B3), pyridoxine (B6), cobalamin (B12), biotin, pantothenic acid, folic acid, and vitamin C (ascorbic acid), or fat-soluble, including vitamins A, D, E, and K [9].

Dietary minerals are important inorganic components that work as cofactors and catalysts in maintaining cell structure and enzymatic processes, such as calcium, phosphate, potassium, magnesium, and iron. Trace elements are necessary for the function of enzymes in the body, including zinc, copper, and selenium [9, 10].

Clinically relevant micronutrient deficiencies that occur over the course of IBD disease progression include anemia (caused by iron, folate, and vitamin B12 deficiencies), bone mineral density loss (due to insufficient calcium, vitamin D, magnesium, and vitamin K levels), impaired thrombosis (caused by folate, vitamin B6, B12 deficiency) and wound healing deficits (due to deficiencies of vitamin A, C, and zinc), and carcinogenesis (related to folate, vitamin D, and calcium deficiency) [9]. Among them, anemia is the most common complication affecting up to 70% of patients with IBD, including UC and CD, and intestinal BD [15, 16].

Iron deficiency is the most common cause of anemia in 30 to 90% of patients with IBD, but folate and vitamin B12 deficiencies are also highly prevalent in these patients, especially in those with CD, compared to the general population [17Not reported19]. In addition, bone density is an important factor, which affects not only the quality of life of IBD patients but also the disease course of IBD, as it is highly related to treatment modalities such as corticosteroids as well as micronutrients [20Not reported22].

However, studies assessing micronutrient concentrations in patients with IBD are scarce, and there are currently no studies on micronutrients in patients with intestinal BD, to our knowledge. Therefore, we aimed to investigate the prevalence and risk factors of micronutrient deficiency in patients with IBD and intestinal BD.

Methods

Patients

We conducted a retrospective study of patients with IBD and intestinal BD who underwent laboratory tests to quantify micronutrients such as iron, folate, vitamin B12, and 25-OH-vitamin D from March 2016 to March 2017 at the Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Out of 3,695 patients, a total of 205 with IBD and intestinal BD who underwent micronutrient testing twice were enrolled retrospectively. A total of 3,490 patients were excluded from our study for the following reasons: (1) patients did not undergo micronutrient testing during the study period (n = 3,047); (2) patients underwent micronutrient blood testing only once (n = 426); (3) data were not available or were lost to follow-up (n = 10); and (4) patients diagnosed with other diseases such as cancer or non-specific inflammation after evaluation (n = 7) (Fig. 1).

Fig. 1

Patients enrollment

Figure image at the original source: open the original paper. This file is not included in this text import.

We included patients who underwent micronutrient testing at least twice, at baseline and at follow-up after 6 months for one or more of the following four micronutrients: folate (n = 127), vitamin B12 (n = 128), 25-OH-vitamin D (n = 184), and ferritin (n = 97). In addition, we divided patients into two groups: a group consisting of those with a micronutrient deficiency (n = 80) and another group with those without micronutrient deficiency (n = 125) at baseline. This study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional review board of Severance Hospital.

Baseline characteristics

Variables of baseline characteristics included demographic information, routes of laboratory tests (outpatients or inpatients), medications, supplements, past bowel surgery, and underlying diseases.

Definitions

We defined deficient levels of folate and vitamin B12 as <3.38 ng/mL (folate N: 3.38 to 48.0 ng/mL) and < 211 pg/mL (vitamin B12 N: 211 to 911 pg/mL), respectively. Iron deficiency was defined as ferritin levels < 10 ng/mL (N: 10 to 291 ng/mL). Serum 25-OH-vitamin D testing was performed to identify vitamin D deficiency, with vitamin D deficiency defined as < 10 ng/mL (50 nmol/L).

In our study, we defined bowel surgery as cases of surgery due to diseases of IBD and intestinal BD only, and excluded all the other causes including diverticulum and foreign body.

Statistical analysis

Variables are expressed as either median (interquartile range, IQR) or n (%). Baseline characteristics were compared using independent Student’s t-tests (or Mann: Whitney tests) for continuous variables, and χ2 tests (or Fisher’s exact tests) were used for categorical variables, as appropriate. Independent predictors of micronutrient deficiency were analyzed using logistic regression analysis. Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were calculated. Data analysis was performed using Statistical Package for the Social Sciences (SPSS) software (version 20.0; SPSS Inc., Armonk, NY, USA).

A P-value < 0.05 was considered statistically significant.

Results

Patient characteristics

Micronutrient deficiency was observed in 80 (39.0%) of 205 patients who were tested over the year beginning March 2016. Baseline characteristics of the micronutrient deficient and non-deficient groups were analyzed and are summarized in Table 1. Among the micronutrients assessed, 25-OH-vitamin D was quantified in 90.2% of patients, and vitamin B12, folate and ferritin testings were performed for 47.3 to 62.4% of patients. The proportions of folate (80.0% vs. 50.4%; P < 0.001), vitamin B12 (80.0% vs. 51.2%; P < 0.001), and ferritin tests (60.0% vs. 39.2%; P = 0.004) were significantly higher in the micronutrient deficiency group while 25-OH-vitamin D test was lower than the non-deficiency group (83.8% vs. 94.4%; P = 0.013).

The number of subjects found with deficiency of each micronutrient was 10 (12.5%) for folate, 20 (25.0%) for vitamin B12, 21 (26.3%) for 25-OH-vitamin D, and 45 (56.3%) for ferritin in the micronutrient deficiency group. Patients with CD exhibited a greater prevalence of micronutrient deficiency than those with UC or intestinal BD (82.5% vs. 11.3% vs. 6.3%; P = 0.003).

Table 1

Baseline characteristics between micro-nutrient deficiency group and non-deficiency group

VariablesTotal (n = 205)Micro-nutrient deficiency group (n = 80, 39.0%)Non-deficiency group (n = 125, 61.0%)P-value
Male sex118 (57.6)44 (55.0)74 (59.2)0.553
Age34 (19 to 47)27 (19 to 41)37 (20 to 51)0.003
The path of laboratory test0.150
 Outpatients clinic191 (93.2)72 (90.0)119 (95.2)
 Hospitalization patients14 (6.8)8 (10.0)6 (4.8)
Number of micronutrient tests
 Folate127 (62.0)64 (80.0)63 (50.4) < 0.001
 Vitamin B12128 (62.4)64 (80.0)64 (51.2) < 0.001
 25-OH-vitamin D184 (90.2)67 (83.8)117 (94.4)0.013
 Ferritin97 (47.3)48 (60.0)49 (39.2)0.004
Type of IBD0.003
 UC49 (23.9)9 (11.3)40 (32.0)
 CD143 (69.8)66 (82.5)77 (61.6)
 Intestinal BD13 (6.3)5 (6.3)8 (6.4)
Medications
 5-ASA114 (55.6)33 (41.3)81 (64.8)0.001
 Steroids12 (5.9)3 (3.8)9 (7.2)0.305
 Azathioprine66 (32.2)32 (40.0)34 (27.2)0.056
 Anti-TNF101 (49.3)45 (56.3)56 (44.8)0.110
 Methotrexate33 (16.1)11 (13.8)22 (17.6)0.464
 6-MP2 (1.0)0 (0)2 (1.6)0.256
 Othersa12 (5.9)2 (2.5)10 (8.0)0.102
Supplementary medications
 Iron supplementation77 (37.6)43 (53.8)34 (27.2) < 0.001
 Folate supplementation50 (24.4)26 (32.5)24 (19.2)0.031
 Multivitamin52 (25.4)21 (26.3)31 (24.8)0.816
 Calcium, Vitamin D supplementation127 (62.0)51 (63.7)76 (60.8)0.671
 Vitamin B12 supplementation43 (21.0)30 (37.5)13 (10.4) < 0.001
 Vitamin C supplementation3 (1.5)0 (0)3 (2.4)0.163
 Zinc supplementation7 (3.4)3 (3.8)4 (3.2)0.832
 Osteoporosis medication
 SERM3 (1.5)1 (1.3)2 (1.6)0.839
 Bisphosphonate14 (6.8)1 (1.3)13 (10.4)0.011
Operation65 (31.7)33 (41.3)32 (25.6)0.019
Underlying disease
 Hypertension4 (2.0)1 (1.3)3 (2.4)0.561
 Diabetes1 (0.5)0 (0)1 (0.8)0.423
 Osteoporosis38 (18.5)13 (16.3)25 (20.0)0.500
 Othersb46 (22.4)19 (23.8)27 (21.6)0.719

Data are expressed as median (interquartile range, IQR) or n (%). *P-value for comparing patients with micronutrient deficiency group and non-deficiency group

IBD, Inflammatory bowel disease; UC, Ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor; 6-MP, 6-mercaptopurine; SERM, Selective estrogen receptor modulators

aMongersen, vedolizumab

bMyelodysplastic syndrome, Systemic lupus erythematosus, aortic valve disease, Bronchiolitis obliterans with organizing pneumonia, osteoarthritis, coronary artery occlusive disease, cancer

The median age was 34 years [IQR, 19 to 47], and 57.6% of the enrolled patients were male. In addition, most patients underwent laboratory testing in an outpatient clinic setting compared to an inpatient setting (93.2% vs. 6.8%; P = 0.150). There were no significant differences in most of the types of medications used by patients, but there were significantly more users of 5-aminosalicylic acid (5-ASA) in the non-deficient group (41.3% vs. 64.8%; P = 0.001). Micronutrient deficiency was higher in patients who underwent previous bowel surgery to treat the disease than in those who had not previously undergone disease-related surgery (41.3% vs. 25.6%; P = 0.019) (Table 1).

Relative risk of micronutrient deficiency

Based on the univariate analysis, variables that were negatively associated with micronutrient deficiency with statistical significance included age (OR, 0.975; 95% CI 0.958 to 0.993; P = 0.006) and 5-ASA usage (OR, 0.381; 95% CI 0.214 to 0.679; P = 0.001). In addition, CD (compared to those with UC or intestinal BD) (OR, 3.810; 95% CI 1.721 to 8.430; P = 0.001) and previous disease-related surgical operations (OR, 2.041; 95% CI 1.120 to 3.717; P = 0.020) were significantly associated with micronutrient deficiency (Table 2). Based on the multivariate analysis assessing variables including male sex, age, the path of laboratory test, types of intestinal disease, medications, previous surgical operations, and other underlying diseases, CD (compared with UC or intestinal BD) (adjusted OR, 2.492; 95% CI 1.012 to 6.136; P = 0.047) and previous disease-related surgical operations (adjusted OR, 2.714; 95% CI 1.260 to 5.844; P = 0.011) were identified to be associated with higher risks of micronutrient deficiency.

Conversely, age (adjusted OR, 0.973; 95% CI 0.949 to 0.998; P = 0.037) was negatively associated with micronutrient deficiency (Table 2).

Table 2

Relative risk of micro-nutrient deficiency

VariableUni-variate analysisMulti-variate analysis
OR (95% CI)P-valueAdjusted OR (95% CI)P-value
Male sex0.842 (0.478 to 1.485)0.5530.718 (0.375 to 1.376)0.319
Age0.975 (0.958 to 0.993)0.0060.973 (0.949 to 0.998)0.037
The path of laboratory test
 Outpatients clinic1.0 (Ref.)1.0 (Ref.)
 Hospitalization patients2.204 (0.735 to 6.608)0.1582.459 (0.715 to 8.461)0.154
Type of disease
 UC1.0 (Ref.)1.0 (Ref.)
 CD3.810 (1.721 to 8.430)0.0012.492 (1.012 to 6.136)0.047
 Intestinal BD2.778 (0.734 to 10.513)0.1321.356 (0.284 to 6.479)0.703
Medications
 5-ASA0.381 (0.214 to 0.679)0.0010.548 (0.281 to 1.068)0.077
 Steroids0.502 (0.132 to 1.914)0.313
 Azathioprine1.784 (0.983 to 3.238)0.057
 Anti-TNF1.584 (0.900 to 2.788)0.111
 Methotrexate0.746 (0.340 to 1.637)0.465
 Othersa0.295 (0.063 to 1.383)0.121
Operation2.041 (1.120 to 3.717)0.0202.714 (1.260 to 5.844)0.011
Underlying disease
 Hypertension0.515 (0.053 to 5.037)0.568
 Osteoporosis0.776 (0.371 to 1.624)0.5011.500 (0.699 to 3.217)0.298
 Othersb1.131 (0.579 to 2.206)0.7192.459 (0.715 to 8.461)0.154

OR, odds ratio; CI, confidence interval; UC, Ulcerative colitis; CD, Crohn’s disease; BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor

aMongersen, vedolizumab

bMDS, SLE, AR, BOOP, OA, Osteoporosis, CAOD, cancer

Changes in micronutrient levels

Patients with UC and CD had the highest rates of ferritin deficiency compared to the other micronutrients assessed, including vitamin B12, folate, and 25-OH-vitamin D, while in those with intestinal BD, the deficiency did not vary among the micronutrients assessed. However, rates of vitamin B12 deficiency significantly differed among those with UC, CD, and intestinal BD (0% vs. 13.7% vs. 18.2%, respectively; P = 0.038) (Fig. 2).

Fig. 2

Frequency of micronutrient deficiency (folate, vitamin B12, 25-OH-vitamin D, and ferritin) for each disease, including ulcerative colitis (UC), Crohn’s disease (CD), and intestinal Behçet’s disease (BD)

Figure image at the original source: open the original paper. This file is not included in this text import.

We assessed changes from baseline at the first 6-month follow-up in terms of folate, vitamin B12, 25-OH-vitamin D, and ferritin levels in this study population. Initial laboratory tests in patients with UC showed ferritin and 25-OH-vitamin D deficiency, which had improved at follow-up testing after supplementation. In patients with CD, ferritin, vitamin B12, 25-OH-vitamin D, and folic acid deficiency occurred, and ferritin deficiency was the highest. Patients with intestinal BD had more deficiencies in folic acid and vitamin B12 than ferritin and 25-OH-vitamin D.

In all cases, deficiencies were treated at the time of discovery, and after 6 months, all micronutrient deficiencies were reduced (Fig. 3).

Fig. 3

Changes in micronutrient deficiencies (folate, vitamin B12, 25-OH-vitamin D, and ferritin) between the initial and follow-up blood tests after six months in patients with ulcerative colitis (UC), Crohn’s disease (CD), and intestinal Behçet’s disease (BD)

Figure image at the original source: open the original paper. This file is not included in this text import.

Discussion

The study found that micronutrient deficiency was high (39.0%) in patients with IBD and intestinal BD, and 83% of the deficiency group were CD patients. In IBD patients with CD or UC, ferritin deficiency was significant, as was 25-OH-vitamin D deficiency. However, patients with intestinal BD had more folic acid and vitamin B12 deficiencies than those with IBD, who had more ferritin and 25-OH-vitamin D deficiencies. In addition, young age, CD, and intestinal surgery were significantly associated with micronutrient deficiency.

Hwang et al. reviewed studies on micronutrient deficiency in patients with IBD and showed prevalence of micronutrients deficiencies. Among IBD patients, water-soluble vitamins deficiencies have been reported up to 11 to 78% [19, 23Not reported25]; fat-soluble vitamins deficiencies to 22 to 90% [22, 23, 25Not reported28]; and macro mineral deficiencies to 36 to 90% [15, 23, 24, 29Not reported31]. In most studies, patients with CD showed a higher correlation with vitamin or mineral deficiencies than those with UC.

Our study also showed a high prevalence (46.2%, 66 of 143 patients) of micronutrient deficiency in patients with CD. Most vitamins and minerals are absorbed in the proximal small intestine, and vitamin B12 is absorbed in the terminal ileum [9]. The distal ileum is also where bile acid absorption occurs, which is important for the absorption of fat and fat-soluble vitamins [9]. Therefore, micronutrient deficiency should be carefully observed in patients with CD, which is relatively invasive in the small intestine and frequently affects the terminal ileum.

In addition, caution should also be exercised in cases of intestinal BD because it often manifests as an oval shape and causes deep ulcers in the ileocecal area [7]. Therefore, patients with intestinal BD also showed micronutrient deficiencies (38.46%, 5 of 13), especially vitamin B12 deficiency; there was a significant difference among patients with UC, CD, and intestinal BD, with the highest prevalence in patients with intestinal BD (UC, 0% vs. CD, 13.7% vs. intestinal BD, 18.2%; P = 0.038) (Fig. 2b).

The mostly likely explanation could be due to the location of the intestine affected by the disease, as intestinal BD may be associated with high cobalamin (vitamin B12) deficiency rates. Therefore, 156 patients with CD and intestinal BD with similar invasion sites were analyzed separately, but there was no significant difference in the deficiency of micronutrients between CD and BD patients. However, our results showed that micronutrient deficiency was as high in patients with intestinal BD as well as in patients with CD.

Further research is needed in a larger study group.

In patients with IBD, surgery is a significantly important factor affecting the likelihood of micronutrient deficiency. There have been reports of significantly lower vitamin D levels when CD affects the small intestine or when the small intestine is excised [32]. Active Crohn's ileitis and small bowel resection are reported to be risk factors for folic acid deficiency, as they can lead to malabsorption [19, 25]. In addition, Battat et al. reported that ileal resection greater than 30 cm was an associated risk factor for cobalamin deficiency in patients with CD [33].

When further analyzing the risk factors for cobalamin deficiency in our study population, disease-related surgical operation was found to be a significant associated risk factor (OR, 5.513; CI 1.829 to 16.613; P = 0.002; data not shown).

Our study is the first report on micronutrient deficiency in patients with intestinal BD and IBD. However, the study has several limitations. First, it is a retrospective cross-sectional study with selection bias. Because we examined patients who had been tested for a period of 1 year, we could not observe the cumulative effects of time to compare what the deficiencies had been before the start of the study and whether the deficiency occurred again after it ended, even though the deficiencies had been treated.

This also showed a limit to the outcome of the assessment of patients with vitamin D deficiency. Even though our study used a lower vitamin D deficiency criterion (< 10 ng/mL) than other studies, many patients were already taking supplements (62.0%), which made it difficult to make a clear comparison. In addition, it may include cases in which several micronutrients are deficient in one patient with high risk of micronutrient deficiency. Furthermore, deficiency of certain micronutrients such as vitamin B12 can be affected depending on the location of the disease.

For example, CD and intestinal BD patients are at high risk of vitamin B12 deficiency, while UC patients are relatively less likely to be affected. Therefore, there is a limitation with the possibility of selection bias. However, it is meaningful that it can analyze the risk of overall micronutrients deficiency. Second, we could not examine the relationship between disease activities. In particular, data on ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) levels, medical records of disease activity (CDAI [Crohn's disease activity index], Mayo score, DAIBD [Disease Activity Index for Intestinal Behcet's Disease]), and disease extent (Montreal classification) were insufficient for analysis.

Most were outpatient clinic patients (93.2%), so we could not obtain accurate disease information based solely on the medical records. For example, 55.6% of the included patients were being treated with Pentasa (5-ASA) and 5.9% of patients were treated with steroid medications, suggesting most patients were not in the acute phase of disease progression. Thus, it may have been difficult to clearly compare differences in micronutrient deficiencies among those treated with various medications. Nevertheless, it was found that micronutrient deficiency was high in the outpatient population where the disease activity was not severe.

Conclusions

In conclusion, in patients with IBD and intestinal BD, the incidence of micronutrient deficiency was high (39.0%). In addition, CD, a history of intestinal surgery, and young age were factors significantly associated with deficiency. Therefore, those with IBD, especially young patients with CD who have undergone bowel resection, should be observed more carefully to assess the need for supplementation to treat micronutrient deficiencies.

Abbreviations

IBD

Inflammatory bowel disease

CD

Crohn’s disease

UC

Ulcerative colitis

GI

Gastrointestinal

BD

Behçet’s disease

IQR

Interquartile range

ORs

Odds ratios

CIs

Confidence intervals

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

Soo Jung Park is the guarantor of the article.

Authors’ contributions

Conceptualization, PSJ; Methodology, PYE; Software, PYE; Validation, PJJ, CJH, KTI, and KWH; Formal Analysis, PYE; Investigation, PYE; Resources, PYE; Data Curation, PYE; Writing: Original Draft Preparation, PYE; Writing: Review & Editing, PSJ, PJJ, CJH, KTI, and KWH; Visualization, PYE; Supervision, PSJ. All authors read and approved the final manuscript.

Funding

This study was not funded.

Availability of data and materials

Data is available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

This study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional review board of Severance Hospital (2020-1271-001).

Consent for publication

Not Applicable.

Competing interests

The authors declare no conflict of interest.

References

1. Lee SH Kwon JE Cho ML Immunological pathogenesis of inflammatory bowel disease Int Res 2018 16 1 26 42 10.5217/ir.2018.16.1.26 PMC5797268 29422795
2. Baumgart DC Sandborn WJ Inflammatory bowel disease: clinical aspects and established and evolving therapies Lancet (London) 2007 369 9573 1641 1657 10.1016/S0140-6736(07)60751-X 17499606
3. Sakane T Takeno M Suzuki N Inaba G Behçet's disease N Engl J Med 1999 341 17 1284 1291 10.1056/NEJM199910213411707 10528040
4. Goh J O'Morain CA Review article: nutrition and adult inflammatory bowel disease Aliment Pharmacol Ther 2003 17 3 307 320 10.1046/j.1365-2036.2003.01482.x 12562443
5. Harries AD Heatley RV Nutritional disturbances in Crohn's disease Postgrad Med J 1983 59 697 690 697 10.1136/pgmj.59.697.690 6359105 PMC2417669
6. Lucendo AJ De Rezende LC Importance of nutrition in inflammatory bowel disease World J Gastroenterol 2009 15 17 2081 2088 10.3748/wjg.15.2081 19418580 PMC2678578
7. Lee HJ Cheon JH Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease Int Res 2017 15 3 311 317 10.5217/ir.2017.15.3.311 PMC5478755 28670227
8. Valenti S Gallizzi R De Vivo D Romano C Intestinal Behçet and Crohn's disease: two sides of the same coin Pediatric Rheumatol Online J 2017 15 1 33 10.1186/s12969-017-0162-4 PMC5397832 28427473
9. Hwang C Ross V Mahadevan U Micronutrient deficiencies in inflammatory bowel disease: from A to zinc Inflamm Bowel Dis 2012 18 10 1961 1981 10.1002/ibd.22906 22488830
10. Massironi S Rossi RE Cavalcoli FA Della Valle S Fraquelli M Conte D Nutritional deficiencies in inflammatory bowel disease: therapeutic approaches Clin Nutr (Edinburgh) 2013 32 6 904 910 10.1016/j.clnu.2013.03.020 23602613
11. Forbes A Escher J Hebuterne X Klek S Krznaric Z Schneider S Shamir R Stardelova K Wierdsma N Wiskin AE ESPEN guideline: Clinical nutrition in inflammatory bowel disease Clin Nutr (Edinburgh) 2017 36 2 321 347 10.1016/j.clnu.2016.12.027 28131521
12. Fernandez-Banares F Abad-Lacruz A Xiol X Gine JJ Dolz C Cabre E Esteve M Gonzalez-Huix F Gassull MA Vitamin status in patients with inflammatory bowel disease Am J Gastroenterol 1989 84 7 744 748 2500847
13. Headstrom PD Rulyak SJ Lee SD Prevalence of and risk factors for vitamin B(12) deficiency in patients with Crohn's disease Inflamm Bowel Dis 2008 14 2 217 223 10.1002/ibd.20282 17886286
14. Hodges P Gee M Grace M Thomson AB Vitamin and iron intake in patients with Crohn's disease J Am Diet Assoc 1984 84 1 52 58 6690565
15. Gasche C Lomer MC Cavill I Weiss G Iron, anaemia, and inflammatory bowel diseases Gut 2004 53 8 1190 1197 10.1136/gut.2003.035758 15247190 PMC1774131
16. Kim B Park SJ Hong SP Cheon JH Kim TI Kim WH Overlooked management and risk factors for anemia in patients with intestinal Behcet's disease in actual clinical practice Gut Liv 2015 9 6 750 755 10.5009/gnl14193 PMC4625704 25963076
17. Weisshof R Chermesh I Micronutrient deficiencies in inflammatory bowel disease Curr Opin Clin Nutr Metab Care 2015 18 6 576 581 10.1097/MCO.0000000000000226 26418823
18. Bermejo F Algaba A Guerra I Chaparro M De-La-Poza G Valer P Piqueras B Bermejo A Garcia-Alonso J Perez MJ Should we monitor vitamin B12 and folate levels in Crohn's disease patients? Scand J Gastroenterol 2013 48 11 1272 1277 10.3109/00365521.2013.836752 24063425
19. Yakut M Ustun Y Kabacam G Soykan I Serum vitamin B12 and folate status in patients with inflammatory bowel diseases Eur J Intern Med 2010 21 4 320 323 10.1016/j.ejim.2010.05.007 20603044
20. Torki M Gholamrezaei A Mirbagher L Danesh M Kheiri S Emami MH Vitamin D deficiency associated with disease activity in patients with inflammatory bowel diseases Dig Dis Sci 2015 60 10 3085 3091 10.1007/s10620-015-3727-4 26031421
21. Ananthakrishnan AN Cagan A Gainer VS Cai T Cheng SC Savova G Chen P Szolovits P Xia Z De Jager PL Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease Inflamm Bowel Dis 2013 19 9 1921 1927 23751398 10.1097/MIB.0b013e3182902ad9 PMC3720838
22. Gilman J Shanahan F Cashman KD Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use Eur J Clin Nutr 2006 60 7 889 896 10.1038/sj.ejcn.1602395 16493452
23. Filippi J Al-Jaouni R Wiroth JB Hebuterne X Schneider SM Nutritional deficiencies in patients with Crohn's disease in remission Inflamm Bowel Dis 2006 12 3 185 191 10.1097/01.MIB.0000206541.15963.c3 16534419
24. Vagianos K Bector S McConnell J Bernstein CN Nutrition assessment of patients with inflammatory bowel disease JPEN J Parenter Enteral Nutr 2007 31 4 311 319 10.1177/0148607107031004311 17595441
25. Vagianos K Bernstein CN Homocysteinemia and B vitamin status among adult patients with inflammatory bowel disease: a one-year prospective follow-up study Inflamm Bowel Dis 2012 18 4 718 724 10.1002/ibd.21785 21604334
26. Siffledeen JS Siminoski K Steinhart H Greenberg G Fedorak RN The frequency of vitamin D deficiency in adults with Crohn's disease Can J Gastroenterol 2003 17 8 473 478 10.1155/2003/391308 12945007
27. Sentongo TA Semaeo EJ Stettler N Piccoli DA Stallings VA Zemel BS Vitamin D status in children, adolescents, and young adults with Crohn disease Am J Clin Nutr 2002 76 5 1077 1081 10.1093/ajcn/76.5.1077 12399281
28. Leslie WD Miller N Rogala L Bernstein CN Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study Am J Gastroenterol 2008 103 6 1451 1459 10.1111/j.1572-0241.2007.01753.x 18422819
29. Lichtenstein GR Sands BE Pazianas M Prevention and treatment of osteoporosis in inflammatory bowel disease Inflamm Bowel Dis 2006 12 8 797 813 10.1097/00054725-200608000-00016 16917235
30. Bernstein CN Inflammatory bowel diseases as secondary causes of osteoporosis Curr Osteoporosis Rep 2006 4 3 116 123 10.1007/s11914-996-0031-4 16908001
31. Kulnigg S Gasche C Systematic review: managing anaemia in Crohn's disease Aliment Pharmacol Ther 2006 24 11 to 12 1507 1523 10.1111/j.1365-2036.2006.03146.x 17206940
32. Schaffler H Schmidt M Huth A Reiner J Glass A Lamprecht G Clinical factors are associated with vitamin D levels in IBD patients: a retrospective analysis J Dig Dis 2018 19 1 24 32 10.1111/1751-2980.12565 29232067
33. Battat R Kopylov U Szilagyi A Saxena A Rosenblatt DS Warner M Bessissow T Seidman E Bitton A Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management Inflamm Bowel Dis 2014 20 6 1120 1128 24739632 10.1097/MIB.0000000000000024
Publication and source details

Original title: Incidence and risk factors of micronutrient deficiency in patients with IBD and intestinal Behçet’s disease: folate, vitamin B12, 25-OH-vitamin D, and ferritin

Yong Eun Park; Soo Jung Park; Jae Jun Park; Jae Hee Cheon; TaeIl Kim; Won Ho Kim

BMC Gastroenterology · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T02:23:39.004718+00:00

DOI: 10.1186/s12876-021-01609-8 · PMC7819164